BriaCell receives New Zealand patent for whole cell cancer technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
July 30, 2025 7:30 AM EDTPHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (BriaCell or the Company), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces that it has been granted New Zealand Patent No. 785587 titled WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF. The patent covers methods of selecting its whole-cell cancer immunotherapy technology for subjects with cancer based on HLA allele profile matching, providing exclusivity through February 27, 2037, and supporting BriaCells precision medicine approach aimed at personalizing immunotherapy for improved patient outcomes.
... More